{"id":238466,"date":"2025-10-20T11:43:08","date_gmt":"2025-10-20T11:43:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/238466\/"},"modified":"2025-10-20T11:43:08","modified_gmt":"2025-10-20T11:43:08","slug":"prokidney-announces-late%e2%80%91breaking-phase-2-regen%e2%80%91007-poster","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/238466\/","title":{"rendered":"ProKidney Announces Late\u2011Breaking Phase 2 REGEN\u2011007 Poster"},"content":{"rendered":"<p>&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p>ProKidney (Nasdaq: PROK) will present two posters at the American Society of Nephrology Kidney Week 2025 in Houston, Nov 6\u20139, 2025. One is a late\u2011breaking poster reporting Phase 2 REGEN\u2011007 study results: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (Session: Late\u2011Breaking Science Posters, Nov 6, 10:00 AM\u201312:00 PM CST, Board #TH\u2011PO1203). The second poster covers the inflammatory profile of the cell therapy candidate rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, Nov 6, 10:00 AM\u201312:00 PM CST, Board #TH\u2011PO0575).<\/p>\n<p>Copies of both posters will be available on the company website after the event and abstracts are listed on the ASN Kidney Week program site.<\/p>\n<p>ProKidney (Nasdaq: PROK) presenter\u00e0 due poster all&#8217;American Society of Nephrology Kidney Week 2025 a Houston, dal 6 al 9 novembre 2025. Uno \u00e8 un poster dell&#8217;ultima ora che riporta i risultati dello studio di fase 2 REGEN-007: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (Session: Late-Breaking Science Posters, 6 novembre, 10:00\u201312:00 CST, Board #TH-PO1203). Il secondo poster riguarda il profilo infiammatorio del candidato alla terapia cellulare rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, 6 novembre, 10:00\u201312:00 CST, Board #TH-PO0575).<\/p>\n<p>Le copie di entrambi i poster saranno disponibili sul sito dell&#8217;azienda dopo l&#8217;evento e gli abstract saranno elencati sul sito del programma ASN Kidney Week.<\/p>\n<p>ProKidney (Nasdaq: PROK) presentar\u00e1 dos carteles en la American Society of Nephrology Kidney Week 2025 en Houston, del 6 al 9 de noviembre de 2025. Uno es un cartel de \u00faltima hora que informa los resultados del estudio de Fase 2 REGEN-007: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (Sesi\u00f3n: Late-Breaking Science Posters, 6 de noviembre, de 10:00 a.m. a 12:00 p.m. CST, Tarjeta #TH-PO1203). El segundo cartel cubre el perfil inflamatorio del candidato de terapia celular rilparencel (Sesi\u00f3n: Development, Stem Cells, and Regenerative Medicine, 6 de noviembre, de 10:00 a.m. a 12:00 p.m. CST, Tarjeta #TH-PO0575).<\/p>\n<p>Copias de ambos carteles estar\u00e1n disponibles en el sitio web de la empresa despu\u00e9s del evento y los res\u00famenes se listar\u00e1n en el sitio del programa ASN Kidney Week.<\/p>\n<p>\ud504\ub85c\ud0a4\ub4dc\ub2c8(PROK) \uc8fc\uc2dd\ud68c\uc0ac\ub294 2025\ub144 11\uc6d4 6\uc77c\ubd80\ud130 9\uc77c\uae4c\uc9c0 \ud734\uc2a4\ud134\uc5d0\uc11c \uc5f4\ub9ac\ub294 American Society of Nephrology Kidney Week 2025\uc5d0\uc11c \ud3ec\uc2a4\ud130 \ub450 \ud3b8\uc744 \ubc1c\ud45c\ud569\ub2c8\ub2e4. \ud558\ub098\ub294 \ub9c8\uac10 \uc784\ubc15 \ud3ec\uc2a4\ud130\ub85c 2\uc0c1 REGEN-007 \uc5f0\uad6c \uacb0\uacfc\ub97c \ubcf4\uace0\ud569\ub2c8\ub2e4: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (\uc138\uc158: Late-Breaking Science Posters, 11\uc6d4 6\uc77c, 10:00\u201312:00 CST, Board #TH-PO1203). \ub450 \ubc88\uc9f8 \ud3ec\uc2a4\ud130\ub294 \uc138\ud3ec \uce58\ub8cc\uc81c rilparencel\uc758 \uc5fc\uc99d \ud504\ub85c\ud30c\uc77c\uc744 \ub2e4\ub8f9\ub2c8\ub2e4 (\uc138\uc158: Development, Stem Cells, and Regenerative Medicine, 11\uc6d4 6\uc77c, 10:00\u201312:00 CST, Board #TH-PO0575).<\/p>\n<p>\uc774\ubca4\ud2b8 \ud6c4 \ub450 \ud3ec\uc2a4\ud130\uc758 \uc0ac\ubcf8\uc774 \ud68c\uc0ac \uc6f9\uc0ac\uc774\ud2b8\uc5d0 \uac8c\uc2dc\ub418\uba70 \ucd08\ub85d\uc740 ASN Kidney Week \ud504\ub85c\uadf8\ub7a8 \uc0ac\uc774\ud2b8\uc5d0 \ubaa9\ub85d\uc73c\ub85c \uc81c\uacf5\ub429\ub2c8\ub2e4.<\/p>\n<p>ProKidney (Nasdaq: PROK) pr\u00e9sentera deux posters lors du Kidney Week 2025 de l&#8217;American Society of Nephrology \u00e0 Houston, du 6 au 9 novembre 2025. L&#8217;un est un poster de derni\u00e8re minute pr\u00e9sentant les r\u00e9sultats de l&#8217;\u00e9tude de phase 2 REGEN-007: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (S\u00e9ance: Late-Breaking Science Posters, 6 novembre, 10h00\u201312h00 CST, Board #TH-PO1203). Le deuxi\u00e8me poster couvre le profil inflammatoire du candidat \u00e0 la th\u00e9rapie cellulaire rilparencel (S\u00e9ance: Development, Stem Cells, and Regenerative Medicine, 6 novembre, 10h00\u201312h00 CST, Board #TH-PO0575).<\/p>\n<p>Des copies des deux posters seront disponibles sur le site Internet de l&#8217;entreprise apr\u00e8s l&#8217;\u00e9v\u00e9nement et les r\u00e9sum\u00e9s seront list\u00e9s sur le site du programme ASN Kidney Week.<\/p>\n<p>ProKidney (Nasdaq: PROK) wird zwei Poster auf der American Society of Nephrology Kidney Week 2025 in Houston, vom 6. bis 9. November 2025, pr\u00e4sentieren. Eines ist ein late-breaking Poster, das Ergebnisse der Phase-2-Studie REGEN-007 berichtet: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (Sitzung: Late-Breaking Science Posters, 6. November, 10:00\u201312:00 CST, Board #TH-PO1203). Der zweite Poster behandelt das inflammatorische Profil des Zelltherapie-Kandidaten rilparencel (Sitzung: Development, Stem Cells, and Regenerative Medicine, 6. November, 10:00\u201312:00 CST, Board #TH-PO0575).<\/p>\n<p>Kopien beider Poster werden nach der Veranstaltung auf der Unternehmenswebsite verf\u00fcgbar sein und die Abstracts sind auf der ASN Kidney Week-Programmseite aufgef\u00fchrt.<\/p>\n<p>ProKidney (\u0628\u0648\u0631\u0635\u0629 \u0646\u0627\u0633\u062f\u0627\u0643: PROK) \u0633\u062a\u0639\u0631\u0636 \u0627\u062b\u0646\u064a\u0646 \u0645\u0646 \u0627\u0644\u0645\u0644\u0635\u0642\u0627\u062a \u0641\u064a \u0623\u0633\u0628\u0648\u0639 \u0627\u0644\u0643\u0644\u0649 2025 \u0644\u062c\u0645\u0639\u064a\u0629 \u0623\u0645\u0631\u0627\u0636 \u0627\u0644\u0643\u0644\u0649 \u0627\u0644\u0623\u0645\u0631\u064a\u0643\u064a\u0629 \u0641\u064a \u0647\u064a\u0648\u0633\u062a\u0646\u060c \u0645\u0646 6 \u0625\u0644\u0649 9 \u0646\u0648\u0641\u0645\u0628\u0631 2025. \u0623\u062d\u062f\u0647\u0645\u0627 \u0645\u0644\u0635\u0642 \u0639\u0627\u062c\u0644 \u0645\u062a\u0623\u062e\u0631 \u064a\u0639\u0644\u0646 \u0639\u0646 \u0646\u062a\u0627\u0626\u062c \u062f\u0631\u0627\u0633\u0629 \u0627\u0644\u0645\u0631\u062d\u0644\u0629 2 REGEN-007: &#8220;Renal Autologous Cell Therapy in Diabetes and CKD&#8221; (\u0627\u0644\u062c\u0644\u0633\u0629: Late-Breaking Science Posters, 6 \u0646\u0648\u0641\u0645\u0628\u0631\u060c 10:00 \u0635\u0628\u0627\u062d\u0627\u064b\u201312:00 \u0638\u0647\u0631\u0627\u064b \u0628\u062a\u0648\u0642\u064a\u062a CST\u060c \u0627\u0644\u0645\u062c\u0644\u0633 #TH-PO1203). \u0627\u0644\u0645\u0644\u0635\u0642 \u0627\u0644\u062b\u0627\u0646\u064a \u064a\u063a\u0637\u064a \u0627\u0644\u0645\u0644\u0641 \u0627\u0644\u0627\u0644\u062a\u0647\u0627\u0628\u064a \u0644\u0644\u0645\u0631\u0634\u062d \u0627\u0644\u0639\u0644\u0627\u062c \u0627\u0644\u062e\u0644\u0648\u064a rilparencel (\u0627\u0644\u062c\u0644\u0633\u0629: Development, Stem Cells, and Regenerative Medicine\u060c 6 \u0646\u0648\u0641\u0645\u0628\u0631\u060c 10:00 \u0635\u0628\u0627\u062d\u0627\u064b\u201312:00 \u0638\u0647\u0631\u0627\u064b \u0628\u062a\u0648\u0642\u064a\u062a CST\u060c \u0627\u0644\u0645\u062c\u0644\u0633 #TH-PO0575).<\/p>\n<p>\u0646\u0633\u062e \u0645\u0646 \u0643\u0644\u0627 \u0627\u0644\u0645\u0644\u0635\u0642\u064a\u0646 \u0633\u062a\u0643\u0648\u0646 \u0645\u062a\u0627\u062d\u0629 \u0639\u0644\u0649 \u0645\u0648\u0642\u0639 \u0627\u0644\u0634\u0631\u0643\u0629 \u0627\u0644\u0625\u0644\u0643\u062a\u0631\u0648\u0646\u064a \u0628\u0639\u062f \u0627\u0644\u062d\u062f\u062b \u0648\u0633\u064a\u062a\u0645 \u0625\u062f\u0631\u0627\u062c \u0627\u0644\u0645\u0644\u062e\u0635\u0627\u062a \u0641\u064a \u0645\u0648\u0642\u0639 \u0628\u0631\u0646\u0627\u0645\u062c ASN Kidney Week.<\/p>\n<p>ProKidney (\u7eb3\u65af\u8fbe\u514b\uff1aPROK) \u5c06\u5728 2025 \u5e74\u7f8e\u56fd\u80be\u810f\u5b66\u4f1a Kidney Week \u4e8e\u4f11\u65af\u987f\u4e3e\u884c\uff0c\u65f6\u95f4\u4e3a 2025 \u5e74 11 \u6708 6 \u65e5\u81f3 9 \u65e5\uff0c\u5c55\u793a\u4e24\u4e2a\u6d77\u62a5\u3002\u4e00\u4e2a\u662f \u665a\u671f\u7a81\u7834\u6d77\u62a5\uff0c\u62a5\u544a Phase 2 REGEN-007 \u7814\u7a76\u7ed3\u679c\uff1a\u201cRenal Autologous Cell Therapy in Diabetes and CKD\u201d\uff08\u4f1a\u8bae\uff1aLate-Breaking Science Posters\uff0c11 \u6708 6 \u65e5\uff0cCST 10:00\u201312:00\uff0c\u677f\u5757 #TH-PO1203\uff09\u3002\u7b2c\u4e8c\u4e2a\u6d77\u62a5\u6db5\u76d6\u7ec6\u80de\u6cbb\u7597\u5019\u9009 rilparencel \u7684\u708e\u75c7\u7279\u5f81\uff08\u4f1a\u8bae\uff1aDevelopment, Stem Cells, and Regenerative Medicine\uff0c11 \u6708 6 \u65e5\uff0cCST 10:00\u201312:00\uff0c\u677f\u5757 #TH-PO0575\uff09\u3002<\/p>\n<p>\u4e24\u4efd\u6d77\u62a5\u7684\u526f\u672c\u5c06\u5728\u6d3b\u52a8\u7ed3\u675f\u540e\u5728\u516c\u53f8\u7f51\u7ad9\u4e0a\u63d0\u4f9b\uff0c\u6458\u8981\u5c06\u5217\u5728 ASN Kidney Week \u9879\u76ee\u7f51\u7ad9\u4e0a\u3002<\/p>\n<p>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      10\/20\/2025 &#8211; 07:30 AM&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n<p align=\"justify\">WINSTON-SALEM, N.C., Oct.  20, 2025  (GLOBE NEWSWIRE) &#8212; ProKidney Corp. (Nasdaq: <a href=\"https:\/\/www.stocktitan.net\/overview\/PROK\" title=\"View PROK stock overview\" class=\"symbol-link\" rel=\"nofollow noopener\" target=\"_blank\">PROK<\/a>)\u00a0(\u201cProKidney\u201d or the \u201cCompany&#8221;), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology\u2019s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.<\/p>\n<p>The titles for the accepted abstracts are provided below and accessible online at: <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=rGe7tRbcYfg9oCfHAtFGSDNQn6s_qfl7vsAVhM3icG7klmoF_QNELzFoibgc-I0QppEgoFOH9rWtdzCQc1VVUn8cwQiZyWo3etDHKWQYsP7553XMHOD2pnBZSO7Re84tmWaM2vV9UQjIiBWb-f4srfwj6UAsnaF135F9mmyv2XVRFCqxeXrLQcQ0Zwfxpa0CbmR3FJaxsG4s_u3A6xBr9saaWt3WU72jngePo7iQ2UQmeU1J4aYC7RSaZcKTwdxh\" target=\"_blank\">https:\/\/www.asn-online.org\/education\/kidneyweek\/2025\/program-search-abstract.aspx<\/a><\/p>\n<p>Late-Breaking Poster Presentation<\/p>\n<p>Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)<br \/>Session Title: Late-Breaking Science Posters [LB-PO]<br \/>Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST<br \/>Poster Board #: TH-PO1203<\/p>\n<p>Other Poster Presentation <\/p>\n<p>Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel<br \/>Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]<br \/>Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST<br \/>Poster Board #: TH-PO0575<\/p>\n<p>Following the event, a copy of the poster presentations will be available on the Company\u2019s website at: <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=rGe7tRbcYfg9oCfHAtFGSBptrKS_73SGF0n2cRKEOj1jCYt0CXSvTdDeX2xItzvfsblE52bgc_VouQen4JRul3z-SQMqAmwkmaj-PzGPTBigvm1x2rHdc1FYIor2jWq3pzdEn-H6S4LKiZ-l1tPVJttDXheIQ4N7AB5Mz_U4EA0=\" target=\"_blank\">https:\/\/prokidney.com\/our-technology\/publications\/<\/a><\/p>\n<p>Additional information on ASN Kidney Week 2025 can be accessed online at: <br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=rGe7tRbcYfg9oCfHAtFGSDNQn6s_qfl7vsAVhM3icG7klmoF_QNELzFoibgc-I0Q0GdE6OpjW7AJdm3p-JuN4sfGKaIKbBW-vcXAdnDeRWNRu0ruPYhBgMYLHVBwGn8VvUrIh6fr5rIH3jxNyFU67PnUQCQq-4OjHBUhVIp6NMU=\" target=\"_blank\">https:\/\/www.asn-online.org\/education\/kidneyweek<\/a><\/p>\n<p align=\"justify\">About ProKidney Corp.<br \/>ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney\u2019s lead product candidate, rilparencel (also known as REACT\u00ae), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit\u00a0<a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=46ua6rOl8HKaHWDjsxAmeJMZld3a19TOeggrVEu8oemjdqmCkGMJ5eWxz_cBuuHPdk6rYhP68PHy2WbGsmGbEBsuKSxOBB8GarHeIhuEYtn3tL4AEIp8OxpqsVe9iwDYUVd5CwqYNNJCkmtJlFKCc2MKfeaW-2dacsRen0zZjMM8vLLWyS-oLarkF9Dwf24-A0JkKrXfJaEpGDmaPp9_HU3jlXTfXY0cG6LRC1Mk7Z-KZRryb0iph7ZZ6fmxBioVdhZ1AQNtv4KPL118Q04bwQ==\" target=\"_blank\">www.prokidney.com<\/a>.<\/p>\n<p>ProKidney Contact<br \/>Ethan Holdaway<br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=_apTk9qmSNaUaVC-74h0ccmKLBlIU6uG_FDPEILY4mAAnMMSn4YDU5M7xwIg2kvS8ofB7ZeYUh4HmCldRABB3eZ0f64m6Pmt_A8Eh68eiKLfYzJ5SubRKDSYvRqzSssg\" target=\"_blank\">Ethan.Holdaway@prokidney.com<\/a><\/p>\n<p>Media Contact<br \/>Audra Friis\u00a0<br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=tAPdVTotpY32m1ccLxMuYzcyzvqujFPvhILwgeEbuBY5e6sN4jAC9DnC-LpqvKydGFuin6yqAklTiMGYGge2-K3akTTFPOrKgN1OS4MoZxiZCelXav9CKQisI6e6_8Ui\" target=\"_blank\">audrafriis@sambrown.com<\/a><\/p>\n<p>Investor Relations Contact<br \/>Daniel Ferry<br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=LzC43TnCvw24Xn9_oCnXu4ayMAzrvHiQCyGpLzvioTIlpBjYoFWxSriijv4GwjEy8Kyvs-cr6bDoSyUp5tuMggKUTvxddN2XDPMJk32_7e0NZv6SBs-PdO3J85LLBgLd\" target=\"_blank\">Daniel@lifesciadvisors.com<\/a><\/p>\n<p> <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/1760960588_190_ti\"\/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/ProKidney.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n  &#13;<br \/>\n&#13;<\/p>\n<p>&#13;<br \/>\n    FAQ  &#13;\n  <\/p>\n<p>&#13;<br \/>\n  &#13;<br \/>\n  &#13;<\/p>\n<p>        When will ProKidney (PROK) present the Phase 2 REGEN-007 results at ASN Kidney Week 2025?<\/p>\n<p>&#13;<br \/>\n          The late\u2011breaking Phase 2 REGEN\u2011007 poster is scheduled for November 6, 2025, 10:00 AM\u201312:00 PM CST (Poster Board #TH\u2011PO1203).&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What is the title of ProKidney&#8217;s late-breaking poster at ASN Kidney Week 2025?<\/p>\n<p>&#13;<br \/>\n          The late\u2011breaking poster is titled &#8220;Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN\u2011007 Study Results)&#8221;.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        When and where is ASN Kidney Week 2025 where PROK will present?<\/p>\n<p>&#13;<br \/>\n          ASN Kidney Week 2025 takes place in Houston, TX, from November 6\u20139, 2025.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What other ProKidney poster will be presented and when is it scheduled?<\/p>\n<p>&#13;<br \/>\n          ProKidney will present &#8220;Cell\u2011Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel&#8221; on November 6, 2025, 10:00 AM\u201312:00 PM CST (Poster Board #TH\u2011PO0575).&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        Where can investors access ProKidney&#8217;s poster presentations after ASN Kidney Week 2025?<\/p>\n<p>&#13;<br \/>\n          Copies of the posters will be available on ProKidney&#8217;s website at https:\/\/prokidney.com\/our-technology\/publications\/ after the event.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        Where can I find the ASN Kidney Week 2025 abstracts for ProKidney (PROK)?<\/p>\n<p>&#13;<br \/>\n          Abstract listings are available on the ASN Kidney Week program search at https:\/\/www.asn-online.org\/education\/kidneyweek\/2025\/program-search-abstract.aspx.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; &#13; &#13; &#13; &#13; &#13; &#13; ProKidney (Nasdaq: PROK) will present two posters at the American&hellip;\n","protected":false},"author":2,"featured_media":238467,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[131853,4,450,13058,64073,131858,451,131856,3,131859,131855,131861,131860,131852,131851,131854,64308,131857,452,453],"class_list":["post-238466","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-asn-kidney-week-2025","tag-breaking-news","tag-breakingnews","tag-cell-therapy","tag-chronic-kidney-disease","tag-ckd","tag-headlines","tag-late-breaking-poster","tag-news","tag-november-6-2025","tag-phase-2","tag-poster-th-po0575","tag-poster-th-po1203","tag-prok","tag-prokidney","tag-regen-007","tag-regenerative-medicine","tag-rilparencel","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/238466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=238466"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/238466\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/238467"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=238466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=238466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=238466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}